26 completed, 5 terminated, 1 active not recruiting, 1 unknown. 23 Phase 2, 12 Phase 1, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 17, Terminated 5, Active not recruiting 1 |
| Phase 1 | 12 | Completed 11, Withdrawn 1 |
| Early Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow saracatinib: new trials by email Literature Review of saracatinib trials Research Report on saracatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Saracatinib Trial TO Prevent FOP AZD0530 Difumarate, Matching placebo - Fibrodysplasia Ossificans Progressiva | Phase 2 | Active not recruiting | Amsterdam UMC, location VUmc | 20 | 2020-08-05 | 2026-09-02 |
| SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis Saracatinib, Placebo Oral Tablet - Parkinson Disease Psychosis | Early Phase 1 | Unknown | King's College London | 30 | 2019-04-11 | 2019-08-13 |
| Saracatinib and Alcohol Drinking Saracatinib, Placebos - Alcohol Drinking | Phase 2 | Completed | Yale University | 50 | 2017-05-09 | 2020-11-13 |
| Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis saracatinib - Pulmonary Lymphangioleiomyomatosis | Phase 2 | Terminated | Baylor College of Medicine | 28 | 2016-04-01 | 2020-07-30 |
| Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers Saracatinib - Alcohol Drinking | Phase 1 | Completed | Yale University | 5 | 2015-11-01 | 2020-01-14 |
| A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease AZD0530 100mg daily, AZD0530 125mg daily, Placebo - Alzheimer's Disease | Phase 2 | Completed | Yale University | 159 | 2014-12-01 | 2019-08-14 |
| The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism 125 mg AZD0530, 50 mg AZD0530, Placebo - Alcoholism | Phase 1 | Completed | Yale University | 49 | 2014-11-01 | 2023-02-24 |
| The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1) Saracatinib - Pulmonary Lymphangioleiomyomatosis | Phase 1 | Completed | Tony Eissa | 9 | 2014-08-01 | 2016-11-30 |
| SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain Saracatinib, Placebo - Cancer | Phase 2 | Completed | Sheffield Teaching Hospitals NHS Foundation Trust | 12 | 2014-03-01 | 2018-04-13 |
| Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease saracatinib, Placebo - Alzheimer's Disease | Phase 1 | Completed | Stephen M. Strittmatter | 24 | 2013-07-01 | 2021-04-23 |
| Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Paclitaxel, Saracatinib, Matched placebo - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 / Phase 3 | Completed | University College, London | 107 | 2011-03-01 | 2015-05-05 |
| Saracatinib in Treating Patients With Prostate Cancer saracatinib, hydrocortisone/placebo - Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 31 | 2010-12-01 | 2015-04-01 |
| Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel AZD0530, Carboplatin, paclitaxel - Cancer, Non Small Cell Lung Cancer | Phase 1 | Withdrawn | AstraZeneca | 27 | 2010-01-01 | 2010-02-04 |
| A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung Saracatinib, Placebo - Osteosarcoma | Phase 2 | Terminated | Sarcoma Alliance for Research through Collaboration | 38 | 2009-03-01 | 2020-01-18 |
| Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male Volunteers [14C] AZD0530 - Healthy | Phase 1 | Completed | AstraZeneca | 6 | 2009-03-01 | 2009-05-21 |
| Relative Bioavailability of Phase II and Phase III Formulations of AZD0530 AZD0530 - Healthy | Phase 1 | Completed | AstraZeneca | 18 | 2008-11-01 | 2009-06-18 |
| A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer Anastrozole, AZD0530 (saracatinib), Placebo - Breast Cancer | Phase 1 / Phase 2 | Completed | Joyce Marie Slingerland, MD | 71 | 2008-10-21 | 2025-01-08 |
| Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer saracatinib, pharmacogenomic studies, pharmacological study - Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2008-10-01 | 2019-04-02 |
| AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours AZD0530 - Solid Tumor | Phase 1 | Completed | AstraZeneca | 18 | 2008-06-01 | 2011-05-16 |
| Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer saracatinib - Invasive Thymoma and Thymic Carcinoma, Recurrent Thymoma and Thymic Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 21 | 2008-06-01 | 2015-06-10 |
Showing 20 of 34. Sign in to see all of them.
Neoplasms (5) · Breast Neoplasms (4) · Ovarian Neoplasms (3) · Pancreatic Neoplasms (3) · Prostatic Neoplasms (3) · Alcohol Drinking (2) · Alzheimer Disease (2) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2) · Stomach Neoplasms (2) · Alcoholism (1) · Bone Diseases (1) · Bone Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Ovarian Epithelial (1)
National Cancer Institute (NCI) (12) · AstraZeneca (8) · Yale University (4) · Amsterdam UMC, location VUmc (1) · Baylor College of Medicine (1) · Joyce Marie Slingerland, MD (1) · King's College London (1) · NCIC Clinical Trials Group (1) · Sarcoma Alliance for Research through Collaboration (1) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · Stephen M. Strittmatter (1) · Tony Eissa (1) · University College, London (1)
United States (21) · United Kingdom (9) · Canada (7) · Netherlands (3) · Norway (3) · Denmark (2) · France (2) · Germany (2) · Japan (2) · Portugal (2) · Spain (2) · Australia (1) · Bulgaria (1) · Peru (1) · Romania (1)
Mary Stuart, MD (4) · Nicola A Hanania, MD (2) · Raj Chetty, MD (2) · Tony Eissa, MD (2) · Cathy Eng (1) · Chris Poole, Prof (1) · Christopher H van Dyck, MD (1) · Christopher van Dyck, MD (1) · Clifford Hudis (1) · Daniel Dilling, MD (1) · David Andrews, Dr (1) · Elisabeth MW Eekhoff, MD, PhD (1) · Francis X McCormack, MD (1) · Frank McCormack, MD (1) · Godfrey D Pearlson, MD (1)
PMID 19238149, PMID 21170669, PMID 22415795, PMID 25070546, PMID 25874001, PMID 26009269, PMID 31329216, PMID 35650602, PMID 36627206, PMID 39800465
N01CM62203 (3), N01CM62201 (2), N01CM62206 (2), P50AA012870 (2), 1UH2TR000967-01 (1), 2009 (1), 2019 (1), 4UH3TR000961-02 (1), 4UH3TR000967-02 (1), N01CM00032 (1), N01CM00071 (1), N01CM00099 (1), N01CM62202 (1), N01CM62204 (1), N01CM62205 (1)